{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000141","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.109469+00:00","generated_at":"2026-05-29T04:08:01.035632+00:00","sec_items":["2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Editas halts reni-cel, cuts 65% workforce, shifts to in vivo gene editing","bullets":["Discontinues ex vivo reni-cel program for sickle cell and beta thalassemia; ends partnering process.","Reduces workforce by ~180 positions (65%); costs of $55-70M for discontinuation, $14-18M for reduction.","Cash runway extended to Q2 2027; focuses on in vivo pipeline, with human proof-of-concept target in ~2 years.","CMO Baisong Mei steps down Dec 31; board members Emma Reeve and Meeta Chatterjee resign; Jessica Hopfield becomes Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000141","json":"https://secwatch.observer/filing/0001650664-24-000141.json","markdown":"https://secwatch.observer/filing/0001650664-24-000141.md","text":"https://secwatch.observer/filing/0001650664-24-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/0001650664-24-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:08:01.035632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}